Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Net Margin (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Net Margin for 3 consecutive years, with 135373.33% as the latest value for Q4 2024.

  • On a quarterly basis, Net Margin fell 13473380.0% to 135373.33% in Q4 2024 year-over-year; TTM through Sep 2025 was 486173.33%, a 48438982.0% decrease, with the full-year FY2024 number at 3767.21%, down 358556.0% from a year prior.
  • Net Margin was 135373.33% for Q4 2024 at Werewolf Therapeutics, down from 1601.84% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 62.79% in Q2 2023 to a low of 135373.33% in Q4 2024.
  • A 3-year average of 14099.97% and a median of 297.74% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 28904bps in 2023, then tumbled -13473380bps in 2024.
  • Werewolf Therapeutics' Net Margin stood at 163.81% in 2022, then crashed by -290bps to 639.53% in 2023, then crashed by -21068bps to 135373.33% in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Net Margin are 135373.33% (Q4 2024), 1601.84% (Q2 2024), and 2182.21% (Q1 2024).